An endothelin antagonist for resistant hypertension

被引：1
|
作者：
Dhaun, Neeraj [1 ,2 ]
Goddard, Jane [2 ]
Webb, David J. [1 ]
机构：
[1] Univ Edinburgh, Clin Pharmacol Unit, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland
[2] Royal Infirm Edinburgh NHS Trust, Dept Renal Med, Edinburgh, Midlothian, Scotland
来源：
LANCET | 2010年 / 375卷 / 9715期
关键词：
BLOOD-PRESSURE; A RECEPTOR;
D O I：
10.1016/S0140-6736(10)60259-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：635 / 635
页数：1
相关论文
共 50 条
  • [1] Endothelin Antagonist for the Treatment of Resistant Hypertension
    Atlas, Steven A.
    CURRENT HYPERTENSION REPORTS, 2008, 10 (06) : 429 - 431
  • [2] Endothelin antagonist for the treatment of resistant hypertension
    Steven A. Atlas
    Current Hypertension Reports, 2008, 10 : 429 - 431
  • [3] Resistant arterial hypertension: endothelin antagonist aprocitentan convinces
    Franke, Katharina
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (11) : 662 - 662
  • [4] Commentary on "Therapy-resistant arterial hypertension: endothelin antagonist aprocitentan convinces"
    Duesing, Rainer
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (11) : 663 - 663
  • [5] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Angeli, Fabio
    Verdecchia, Paolo
    Reboldi, Gianpaolo
    CARDIOLOGY AND THERAPY, 2021, 10 (02) : 397 - 406
  • [6] Aprocitentan Dual endothelin ETA/ETB receptor antagonist Treatment of resistant hypertension
    Warden, B. A.
    Duell, P. B.
    DRUGS OF THE FUTURE, 2021, 46 (08) : 595 - 611
  • [7] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Fabio Angeli
    Paolo Verdecchia
    Gianpaolo Reboldi
    Cardiology and Therapy, 2021, 10 : 397 - 406
  • [8] Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
    McCoy, Emily K.
    Lisenby, Katelin M.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 699 - 766
  • [9] Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension
    Brussee, Janneke M.
    Sidharta, Patricia N.
    Dingemanse, Jasper
    Krause, Andreas
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (03) : 243 - 252
  • [10] Investigating the endothelin receptor antagonist aprocitentan in resistant hypertension: design and baseline characteristics of the PRECISION study
    Danaietash, P.
    Verweij, P.
    Wang, J.
    Dresser, G.
    Kantola, I.
    Lawrence, M. K.
    Narkiewicz, K.
    Schlaich, M.
    Bellet, M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2362 - 2362
12345